Skip to main content
Clinical Trials/NCT06298825
NCT06298825
Not yet recruiting
Not Applicable

Effect of Sarcopenia on Prognosis of Patients With Acute Decompensated Heart Failure: a Prospective, Multi-center, Observational Cohort Study

Guangdong Provincial People's Hospital1 site in 1 country500 target enrollmentApril 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Decompensated Heart Failure
Sponsor
Guangdong Provincial People's Hospital
Enrollment
500
Locations
1
Primary Endpoint
All-cause mortality
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is a prospective, multi-center, investigator-initiated observational cohort study. Enrollment with a minimum of of 195 cases each for patients with and without sarcopenia. Each patient is followed up for 6 month, 1 year, 2 years or until the occurrence of death.This study will examine the correlation between sarcopenia and prognosis in different subgroups of patients, and explore the additive effect of different comorbidities and sarcopenia on prognosis in patients with acute decompensated heart failure.

Detailed Description

Guangdong Provincial People's Hospital will be the lead center, with an additional 4 hospitals designated as satellite centers for the study. Enrollment of up to 500 participants adults aged over 18 years hospitalized for ADHF is planned, with a minimum of of 195 cases each for patients with and without sarcopenia The sympathetic nervous activity, psychosocial factors, quality of life, physical function and baseline physical activity will also be observed and recorded at baseline. Each patient is followed up for 6 month, 1 year, 2 years or until the occurrence of death. The primary clinical outcome is all-cause mortality at 6 months. Other clinical outcomes of interest include cardiovascular mortality, all-cause hospitalisation, HF hospitalisation, the frequency and length of hospitalization of patient readmitted and survival time from enrollment to death of deceased patients. This study will examine the correlation between sarcopenia and prognosis in different subgroups of patients, and explore the additive effect of different comorbidities and sarcopenia on prognosis in patients with acute decompensated heart failure. S-ADHF will provide important information and evidence on the clinical aspects of sarcopenia in patients with ADHF, and will potentially and contribute to accurate risk stratification and optimal clinical management for patient with ADHF.

Registry
clinicaltrials.gov
Start Date
April 1, 2024
End Date
June 1, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Huan Ma

Deputy Director of Cardiology, Director of the Department of Cardiac Rehabilitation

Guangdong Provincial People's Hospital

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • At least one symptom of heart failure upon admission:Dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea or exertional fatigue.
  • At least two of the signs of heart failure (HF):
  • Distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, or increased jugular venous pressure/central venous pressure/pulmonary capillary wedge pressure.
  • Pulmonary edema or pulmonary congestion (rales or chest X-ray/CT evidence of pulmonary congestion).
  • Peripheral edema. Elevated B-type natriuretic peptide (\>100 pg/ml) or elevated N-Terminal Pro-Brain Natriuretic Peptide (\>300 pg/ml).
  • Willingness to provide informed consent and cooperate with the follow-up

Exclusion Criteria

  • Unable to understand and comply with protocol or to give informed consent
  • End-stage diseases other than heart failure, life expectancy \<1 year, such as malignant tumors
  • Current or planned participation in a clinical trial.

Outcomes

Primary Outcomes

All-cause mortality

Time Frame: 6 months

Number of all-cause death 6 months from hospital discharge

Secondary Outcomes

  • All-cause mortality(1 year and 2 year)
  • Cardiovascular mortality(6 moths, 1year and 2 years)
  • All-cause hospitalisation(6 moths, 1year and 2 years)
  • HF hospitalisation(6 moths, 1year and 2 years)

Study Sites (1)

Loading locations...

Similar Trials